Phenotypic and Molecular Characterisation of Staphylococcus Aureus with Reduced Vancomycin Susceptibility Derivated in Vitro

Vancomycin has been the primary agent used to treat serious Methicillin-resistant Staphylococcus aureus (MRSA) infection for many years. However, the rise of MRSA infection rates and the extensive use of vancomycin have led to the emergence of reduced vancomycin susceptibility. Therefore, four typic...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jia, Pang, Long, Ma, Xiao Xue, Hu, Jian, Tian, Yuan, Yang, Ya Li, Sun, Dan Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2018
Materias:
Regular Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6227741/
https://www.ncbi.nlm.nih.gov/pubmed/30426085
http://dx.doi.org/10.1515/med-2018-0071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6227741/
https://www.ncbi.nlm.nih.gov/pubmed/30426085
http://dx.doi.org/10.1515/med-2018-0071

Ejemplares similares